NK/T Cell Lymphoma Nos
5 clinical trials · Condition
◉ Watch NK/T Cell Lymphoma Nos
| Record | Firm | Date |
|---|---|---|
| Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed/Refractory NK/T-cell Lymphoma (NCT05316246) | Shanghai Zhongshan Hospital | 2022-06-01 |
| A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL) (NCT04365036) | Sun Yat-sen University | 2020-05-03 |
| Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma (NCT04231370) | Beijing Tongren Hospital | 2020-04-01 |
| Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type (NCT04127227) | Sun Yat-sen University | 2019-10-09 |
| Pegaspargase-COEP Chemotherapy Combined With Radiotherapy for Extra-nodal NK/T Cell Lymphoma (NCT04484506) | Peking University | 2011-10-20 |
Track NK/T Cell Lymphoma Nos automatically
Every clearance here is in the API, with alerts when new ones post.